首次人体人表皮生长因子受体2靶向显像:89Zr-帕妥珠单抗PET/CT在乳腺癌患者中的剂量学与临床应用
这项首次人体前瞻性临床试验纳入6例HER2阳性转移性乳腺癌患者,评估89Zr-帕妥珠单抗PET/CT的安全性、剂量学与生物分布。未发生毒性,肝脏、肾脏和心壁吸收剂量最高,平均有效剂量为0.54 ± 0.07 mSv/MBq,给药后5-8 d显像最佳,并能显示多部位HER2阳性病灶,包括经切除证实的脑转移HER2阳性。
要点
- 6例HER2阳性转移性乳腺癌患者接受89Zr-帕妥珠单抗PET/CT,未发生毒性。
- 肝脏、肾脏和心壁吸收剂量最高,平均有效剂量为0.54 ± 0.07 mSv/MBq。
- 给药后5-8 d显像最佳,可显示多部位HER2阳性病灶,包括脑转移。
核心结论
- 这项首次人体研究证实了89Zr-帕妥珠单抗PET/CT的安全性、剂量学、生物分布及成功的HER2靶向显像。
- 潜在临床应用包括评估可能无法活检病灶的HER2状态以及评估HER2异质性。
研究设计与样本
- 经机构审查委员会批准的前瞻性临床试验,纳入HER2阳性乳腺癌且存在远处转移证据的患者。
- 帕妥珠单抗经去铁胺偶联后用89Zr标记,患者接受74 MBq 89Zr-帕妥珠单抗PET/CT,帕妥珠单抗总抗体量为20-50 mg。
- 在8 d内进行PET/CT、全身探头计数和采血,以评估药代动力学、生物分布和剂量学。
主要发现
- 共6例HER2阳性转移性乳腺癌患者入组并接受89Zr-帕妥珠单抗,未发生毒性。
- OLINDA剂量学估算显示,吸收剂量最高的器官为肝脏(1.75 ± 0.21 mGy/MBq)、肾脏(1.27 ± 0.28 mGy/MBq)和心壁(1.22 ± 0.16 mGy/MBq),平均有效剂量为0.54 ± 0.07 mSv/MBq。
- PET/CT显示给药后5-8 d显像最佳,89Zr-帕妥珠单抗能够显示多部位恶性肿瘤并提示其为HER2阳性。
- 在2例同时患有已知HER2阳性和HER2阴性原发乳腺癌及脑转移的患者中,89Zr-帕妥珠单抗PET/CT提示脑转移为HER2阳性;其中1例后续脑转移灶切除证实为HER2阳性病变,确认该摄取为HER2阳性恶性肿瘤的真阳性结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of 89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)-targeted imaging in patients with HER2-positive breast cancer. Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an institutional review board-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with 89Zr. Patients underwent PET/CT with 74 MBq of 89Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab. PET/CT, whole-body probe counts, and blood drawing were performed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry. PET/CT images were evaluated for the ability to visualize HER2-positive metastases. Results: Six patients with HER2-positive metastatic breast cancer were enrolled and administered 89Zr-pertuzumab. No toxicities occurred. Dosimetry estimates from OLINDA demonstrated that the organs receiving the highest doses (mean ± SD) were the liver (1.75 ± 0.21 mGy/MBq), the kidneys (1.27 ± 0.28 mGy/MBq), and the heart wall (1.22 ± 0.16 mGy/MBq), with an average effective dose of 0.54 ± 0.07 mSv/MBq. PET/CT demonstrated optimal imaging 5-8 d after administration. 89Zr-pertuzumab was able to image multiple sites of malignancy and suggested that they were HER2-positive. In 2 patients with both known HER2-positive and HER2-negative primary breast cancers and brain metastases, 89Zr-pertuzumab PET/CT suggested that the brain metastases were HER2-positive. In 1 of the 2 patients, subsequent resection of a brain metastasis proved HER2-positive disease, confirming that the 89Zr-pertuzumab avidity was a true-positive result for HER2-positive malignancy. Conclusion: This first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging with 89Zr-pertuzumab PET/CT. Potential clinical applications include assessment of the HER2 status of lesions that may not be accessible to biopsy and assessment of HER2 heterogeneity.
引用
- Ulaner GA, Lyashchenko SK, Riedl C, et al. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med. 2017. PMID: 29146695. doi:10.2967/jnumed.117.202010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。